Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the results and potential impact from the phase 3 CEPHEUS trial.

Targeted Oncology co-hosts Kristie L. Kahl and Andrew Svonavec highlight abstracts for community oncologists to look out for ...

TERN-701 showed promising early results, with significant molecular responses and a strong safety profile in heavily ...

Joe DePinto, MBA, discusses the complexity of the cell and gene therapy ecosystem and the need for collaboration with ...

Bertrand Y. Tuan, MD, hematologist/oncologist at Pacific Hematology Oncology Associates and California Pacific Medical Center ...

During a Case-Based Roundtable® event, Daniel J. George, MD and participants discussed combination regimens for intermediate ...

Susan L. Slager, PhD, discusses some of the recommendations for genetic testing in individuals with a family history of ...

R289, a dual IRAK1/4 inhibitor, has received fast track status from the FDA for treating transfusion-dependent lower-risk MDS ...

Barbara O’Brien, MD, discusses the next steps of the phase 2 TBCRC049 study for the treatment of patients with HER2-positive ...

The FDA granted approval to nilotinib (Danziten) on November 14, 2024, for the treatment of adult patients with newly ...

The combination of HBI-8000 and nivolumab induced a response in nearly two-thirds of patients with advanced melanoma and no ...

In an interview, Vincent Law, of Moffitt Cancer Center, discussed a new study that offers hope for patients with melanoma ...